Janus Henderson Group
ANIK icon

Janus Henderson Group’s Anika Therapeutics ANIK Stock Holding History

Janus Henderson Group’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-304,556
Closed -$5.67M – 2550
2023
Q3 		$5.67M Sell
304,556
-68,387
-18% -$1.42M ﹤0.01% 787
2023
Q2 		$9.69M Sell
372,943
-309,181
-45% -$8.27M 0.01% 697
2023
Q1 		$19.6M Buy
682,124
+68,418
+11% +$2.04M 0.01% 584
2022
Q4 		$18.2M Sell
613,706
-1,491
-0.2% -$42.4K 0.01% 589
2022
Q3 		$14.6M Sell
615,197
-69,564
-10% -$1.6M 0.01% 609
2022
Q2 		$15.3M Sell
684,761
-5
-0% -$112 0.01% 612
2022
Q1 		$17.2M Buy
684,766
+112,871
+20% +$3.44M 0.01% 781
2021
Q4 		$20.5M Buy
571,895
+108,110
+23% +$4.33M 0.01% 781
2021
Q3 		$19.7M Buy
463,785
+259,147
+127% +$10.7M 0.01% 800
2021
Q2 		$8.86M Buy
+204,638
New +$8.72M ﹤0.01% 949
2019
Q1 		– Sell
-7,858
Closed -$264K – 1345
2018
Q4 		$264K Buy
7,858
+168
+2% +$6.06K ﹤0.01% 1286
2018
Q3 		$324K Buy
+7,690
New +$304K ﹤0.01% 1372

Other funds holding ANIK

TI
Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Janus Henderson Group's ANIK Position: Q4 2023 in Review

Janus Henderson Group sold out of Anika Therapeutics (ANIK) in Q4 2023, closing a stake of 304,556 shares — an estimated $5.67M sold.

Janus Henderson Group first reported a position in ANIK in Q3 2018 and held it in 12 quarters. The position peaked at $20.5M in Q4 2021. 117 funds tracked by Wall St. Rank hold ANIK as of Q4 2023.

  • Janus Henderson Group reported no remaining Anika Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Janus Henderson Group sold 304,556 Anika Therapeutics shares in Q4 2023, an estimated $5.67M.
  • Janus Henderson Group first reported a position in Anika Therapeutics in Q3 2018 and held it in 12 quarters.
  • Janus Henderson Group's Anika Therapeutics position peaked at $20.5M in Q4 2021.
  • 117 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2023.

Based on Janus Henderson Group's 13F filing for Q4 2023, filed 14 Feb 2024.